Zai Lab Ltd
ZLABNasdaq
$20.20
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↓ -43.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$22.4B
Enterprise Value
$21.9B
P/E
—
P/S
49.3
P/B
33.8
EV/EBITDA
—
PEG
—
FCF Yield
-0.5%
Dividend Yield
—
Revenue (TTM)
$453.3M
Net Income (TTM)
-$178.1M
Free Cash Flow (TTM)
-$108.8M
Gross Margin
—
Operating Margin
-53.5%
Net Margin
-39.3%
ROE
-26.9%
ROIC
-89.3%
Debt / Equity
0.3
Net Cash
$447.5M
Return 1Y
-43.9%
Company profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia. It also develops Odronextamab, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer
- CEO
- Ying Du
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,950
- Website
- zailaboratory.com
Management & directors
- Du YingChairperson & CEO
- Chen YajingChief Financial Officer
- Edmondson Frazor Titus IiiChief Legal Officer
- Amado RafaelSee Remarks
- Smiley Joshua LSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
ZLAB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$99.6M↓ -6.5%
Diluted EPS-$0.05↑ +25.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $49.0M | $144.3M | $215.0M | $266.7M | $399.0M | $460.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$301.8M | -$700.1M | -$404.4M | -$366.6M | -$282.1M | -$229.4M |
| Net income | -$268.9M | -$704.5M | -$443.3M | -$334.6M | -$257.1M | -$175.5M |
| Diluted EPS | -$0.35 | -$0.76 | -$0.46 | -$0.35 | -$0.26 | -$0.16 |
| Operating cash flow | -$216.1M | -$549.2M | -$367.6M | -$198.2M | -$214.9M | -$150.8M |
| Free cash flow | -$226.2M | -$567.5M | -$392.2M | -$205.4M | -$220.5M | -$158.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -616.4% | -485.1% | -188.0% | -137.4% | -70.7% | -49.9% |
| Net margin | -549.3% | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100.5M | $102.3M | $109.1M | $106.5M | $110.0M | $116.1M | $127.6M | $99.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$76.1M | -$67.9M | -$67.9M | -$56.3M | -$54.9M | -$48.8M | -$69.4M | -$69.4M |
| Net income | -$80.3M | -$41.7M | -$81.7M | -$48.4M | -$40.7M | -$36.0M | -$50.4M | -$51.0M |
| Diluted EPS | -$0.08 | -$0.04 | -$0.09 | -$0.04 | -$0.04 | -$0.03 | -$0.05 | -$0.05 |
| Operating cash flow | -$42.2M | -$26.8M | -$55.8M | -$61.7M | -$31.0M | -$32.0M | -$26.0M | -$11.9M |
| Free cash flow | -$42.9M | -$28.2M | -$58.4M | -$63.2M | -$33.9M | -$35.0M | -$26.7M | -$13.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -75.7% | -66.4% | -62.2% | -52.9% | -49.9% | -42.1% | -54.4% | -69.7% |
| Net margin | -79.9% | -40.7% | -74.9% | -45.5% | -37.0% | -31.0% | -39.5% | -51.2% |
Company news
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Du Ying· Chairperson & CEO | Tax withholding | 4,348 | $19.12 | $83,133.76 | filing |
| 2026-07-02 | Du Ying· Chairperson & CEO | Option exercise | 11,048 | — | — | filing |
| 2026-07-01 | Du Ying· Chairperson & CEO | Tax withholding | 7,083 | $19.15 | $135,639.45 | filing |
| 2026-07-01 | GAYNOR RICHARD | Buy | 1,736 | $19.05 | $33,070.80 | filing |
| 2026-07-01 | Du Ying· Chairperson & CEO | Option exercise | 18,000 | — | — | filing |
| 2026-06-30 | Du Ying· Chairperson & CEO | Sale | 7,026 | $18.53 | $130,219.88 | filing |
| 2026-06-29 | Du Ying· Chairperson & CEO | Option exercise | 17,970 | — | — | filing |
| 2026-06-26 | Du Ying· Chairperson & CEO | Sale | 24,543 | $17.46 | $428,545.32 | filing |
| 2026-06-26 | Edmondson Frazor Titus III· Chief Legal Officer | Sale | 4,103 | $17.46 | $71,642.48 | filing |
| 2026-06-26 | Chen Yajing· Chief Financial Officer | Sale | 2,264 | $17.46 | $39,531.70 | filing |
| 2026-06-25 | Edmondson Frazor Titus III· Chief Legal Officer | Option exercise | 14,600 | — | — | filing |
| 2026-06-25 | Du Ying· Chairperson & CEO | Option exercise | 58,800 | — | — | filing |
| 2026-06-25 | Chen Yajing· Chief Financial Officer | Option exercise | 6,250 | — | — | filing |
| 2026-06-22 | Lis William | Sale | 7,040 | $18.09 | $127,353.60 | filing |
| 2026-06-17 | GAYNOR RICHARD | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | Morrison Scott W | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | Vounatsos Michel | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | Lis William | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | DIEKMAN JOHN D | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | WIRTH PETER | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | MOULDER LEON O JR | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-06-17 | Leung Nisa | Award | 22,371 | $0.00 | $0.00 | filing |
| 2026-05-27 | Du Ying· Chairperson & CEO | Gift | 33,993 | $0.00 | $0.00 | filing |
| 2026-05-27 | Du Ying· Chairperson & CEO | Gift | 53,850 | $0.00 | $0.00 | filing |
| 2026-05-26 | Du Ying· Chairperson & CEO | Gift | 19,857 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.